On July 10, 2024, Zydus Lifesciences Limited announced that the company received final approval from the United States Food and Drug Administration (USFDA) to market Sacubitril and Valsartan Tablets, available in dosages of 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg (branded as Entresto® tablets in the US). This combination medication is prescribed …